NBIX vs TONX · P/E 45, rev $1.77B vs rev $18.0M
Neurocrine Biosciences Inc (NBIX) versus TON Strategy Co (TONX) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
TON Strategy Co (TONX) is a software - application company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TONX revenue for 2026-06-30 was $18.0M. Net income was -$14.3M. TONX currently screens at market cap $198.4M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TONX currently screens at market cap $198.4M.
Not investment advice. Open the NBIX and TONX stock pages for the full models.
Not investment advice.